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ABSTRACT
Phase II metabolism is prominently governed by UDP-
glucuronosyltransferases (UGTs) in humans. These enzymes
regulate the bioactivity of many drugs and endogenous small
molecules in many organs, including the liver, a major site of
regulation by the glucuronidation pathway. This study de-
termined the expression of hepatic UGTs by targeted proteo-
mics in 48 liver samples and by measuring the glucuronidation
activity using probe substrates. It demonstrates the sensitivity
and accuracy of nano-ultra-performance liquid chromatography
with tandem mass spectrometry to establish the complex expres-
sion profiles of 14 hepatic UGTs in a single analysis. UGT2B7 is the
most abundant UGT in our collection of livers, expressed at 69
pmol/mg microsomal proteins, whereas UGT1A1, UGT1A4, UGT2B4,
and UGT2B15 are similarly abundant, averaging 30–34 pmol/mg pro-
teins. The average relative abundance of these five UGTs represents
81% of the measured hepatic UGTs. Our data further highlight the
strong relationships in the expression of several UGTs. Most
notably, UGT1A4 correlates with most measured UGTs, and the
expression levels of UGT2B4/UGT2B7 displayed the strongest
correlation. However, significant interindividual variability is observed
for all UGTs, both at the level of enzyme concentrations and activity
(coefficient of variation: 45%–184%). The reliability of targeted
proteomics quantification is supported by the high correlation
between UGT concentration and activity. Collectively, these findings
expand our understanding of hepatic UGT profiles by establishing
absolute hepatic concentrations of 14 UGTs and further suggest
coregulated expression between most abundant hepatic UGTs. Data
support the value of multiplexed targeted quantitative proteomics to
accurately assess specific UGT concentrations in liver samples and
hepatic glucuronidation potential.
Introduction
The liver is a key organ for the metabolism of drugs and endogenous
compounds such as hormones and bile acids. Through the expression of
a complex cocktail of enzymes such as uridine 59-diphosphoglucu-
ronosyltransferases (UGTs), the biochemical properties and bioactivity
of these compounds are highly regulated by the liver. Glucuronidation
contributes 35% of the phase II drug metabolic pathways and is
involved in the clearance of 55% of the 200 most prescribed drugs
(Guillemette et al., 2014). The liver expresses a diversified array of
UGTs, with 12 of the 16 UGT1A and UGT2B proteins (Guillemette
et al., 2014).
The expression profile of UGTs was first described using various
techniques based on mRNA and immunochemical quantification
(Court et al., 2012). However, significant quantitative inaccuracy
arises from the lack of correlation between mRNA and protein
expression levels and the high sequence similarity among UGTs
(Margaillan et al., 2015). A number of research groups including
ours have developed mass spectrometry-based methods to quantify
UGTs in human tissues (Table 1) (Harbourt et al., 2012; Ohtsuki
et al., 2012; Fallon et al., 2013b; Achour et al., 2014; Groer et al.,
2014; Sato et al., 2014; Yan et al., 2015). Despite the higher
precision and specificity in UGT quantification, a strong inter-
individual variability in the expression profile of all UGTs has been
highlighted by all studies; consequently, substantial differences in
UGT quantification have arisen from the different studies. Genetic
variation importantly influences UGT expression (Guillemette et al.,
2010), such as the well-characterized variant UGT1A1*28 (rs8175347;
[TA]6.7) associated with lower hepatic conjugation of UGT1A1
substrates (Innocenti et al., 2004).
To expand our understanding of hepatic UGT profiles, we used
targeted proteomics quantification in 48 liver specimens to determine
UGT protein expression. The reliability of this approach as a pre-
dictor of hepatic drug metabolizing capacity was then established
by correlating the UGT expression levels with glucuronidation
activity by the use of probe substrates and, for UGT1A1, to
promoter genotype. Our quantification reveals important diversity
and variability in the UGT protein expression profiles, highlights
UGT2B7, UGT1A1, UGT2B4, UGT1A4, and UGT2B15 as the
most expressed in the liver, and finds significant correlations with
probe substrate activities.
Materials and Methods
Human liver microsomes (HLM) were obtained from nontumorous liver
samples (n = 48) and were from an equal number of males and females of
Caucasian origin, as described elsewhere (Sumida et al., 1999; Gomes et al.,
2009). The institutional boards approved the study, and written consent was
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obtained from all patients concerning the use of their tissues for research
purposes. Total protein concentration was measured using a bicinchoninic acid
assay (ThermoFisher Scientific, Ottawa, ON, Canada). UGT1A1 (rs8175347;
[TA]6.7) was genotyped by sequencing PCR products as described by
Thibaudeau et al. (2006). Fourteen UGT1A and UGT2B proteins were
quantified (Fallon et al., 2013a,b; Margaillan et al., 2015), not including
UGT2B11, UGT2B28, and UGT2As, for which specific signature peptides had
not been obtained.
Before quantification, each HLM was diluted to 1 mg/ml with 50 mM
ammonium bicarbonate. For all samples, 20 mg of microsomal protein was
denatured, reduced, carbamidomethylated, and then digested with trypsin. A
mixture of stable isotope-labeled standard peptides (Thermo Biopolymers,
Ulm, Germany) corresponding to the selected signature peptides of each UGT
was added to each sample.
Quantitative analysis was achieved on a nanoACQUITY binary pump
system coupled to a QTRAP 5500 mass spectrometer (AB SCIEX, Framingham,
MA) using two multiple reaction monitoring (MRM) transitions to quantify each
UGT, as described recently (Fallon et al., 2013a,b). The limit of detection
was 0.2 pmol/mg proteins for all UGTs with the exception of UGT1A9, for
which it was 1.0 pmol/mg protein.
Glucuronidation assays were conducted on HLMs (4 mg) in a final
volume of 100 ml with a panel of UGT probe substrates. Bilirubin
(10 mM; 10 minutes), deferiprone (20 mM, 60 minutes), propofol (50 mM,
30 minutes), and zidovudine (AZT; 500 mM, 60 minutes) were obtained from
Sigma-Aldrich (St. Louis, MO). Estradiol (100 mM, 180 minutes) was obtained
from Steraloids (Newport, RI). Tacrolimus (200 mM, 60 minutes) was obtained
from Cell Signaling Technologies (Danvers, MA). Glucuronides were measured
by mass spectrometry-based methods (Lepine et al., 2004; Benoit-Biancamano
et al., 2009).
Statistical correlation scores were determined by a Spearman correlation test
using XLSTAT (Addinsoft, New York, NY). The statistically significant
difference between rs8175347 and UGT1A1 expression and activity was
determined by a Kruskal-Wallis analysis of variance using GraphPad Prism
Software (La Jolla, CA).
Results and Discussion
Quantification of Hepatic UGTs by Targeted Proteomics.
Absolute quantification of UGT1As and UGT2Bs in liver microsomes
was conducted by acquiring MRMs for specific signature peptides and
their heavy labeled standards in a collection of 48 adult livers. UGT2B7
was the most abundant UGT, with an average concentration of
69.4 pmol/mg protein (Fig. 1A). The average concentrations of
UGT1A1, UGT1A4, UGT2B4, and UGT2B15 were in a similar
range, about half that of UGT2B7, at 30.2–34.3 pmol/mg proteins. The
relative abundance of these five UGTs represents over 80% of
the measured hepatic UGTs (Fig. 1B). Moderate levels of UGT1A9
(22.7 pmol/mg proteins) and UGT1A6 (11.3 pmol/mg proteins) were
measured, and the average concentrations of other measurable UGTs
were below 7 pmol/mg protein. However, the average concentration
of UGT2B10 (6.9 pmol/mg proteins) is likely underestimated
because the signature peptide lies in a polymorphic region. Of note,
UGT2B15 was on average 5 to 6 times more abundant than
UGT2B17 in the liver. This is in part due to undetectable levels of
UGT2B17 in 25% of the liver samples, reflected by the high
coefficient of variation (CV 183%) for this protein (Fig. 1A) and
likely is caused by the common deletion of the gene (McCarroll
et al., 2006). A wide variability in the expression level of the other
expressed UGTs was also observed, with CVs of 45%–89%. Consistent
with previous reports, UGT1A5, UGT1A7, UGT1A8, and UGT1A10
were not detected in HLMs.
Several recent studies have addressed the absolute concentration
of hepatic UGTs by a targeted mass spectrometry approach, enabling
comparisons of UGT concentrations among the different liver
sample collections (Table 1). The measured concentrations of UGTs
in the current study are well in line with those measured in another
collection comprising 60 livers, using the same signature peptides
and a similar approach (Fallon et al., 2013b). Both studies revealed
UGT2B7 as the most abundant, and UGT1A1, UGT1A4, UGT2B4,
and UGT2B15 as the next most abundant UGTs. Although their
rank order differs slightly, the concentrations determined for these
UGTs are in similar ranges, clearly indicating the reproducibility of
the approach. All other studies but one (Achour et al., 2014) revealed
the predominant expression of UGT2B7 in the liver, despite some
important differences in absolute concentrations determined, as was
also the case for other main liver UGTs. Discrepancies in absolute
concentrations may arise from interindividual variability or the ethnic
origins of the human samples, and the choice of signature peptides
can also certainly influence quantification. The quantitative approach
TABLE 1
UGT quantification by targeted mass spectrometry (MRM) in this and previous studies
UGT Enzyme
Reported Mean UGT Concentration (n livers in study)
Ohtsuki et al., 2012
(n = 17)
Harbourt et al., 2012
(n = 33)
Sato et al., 2014
(n = 16)
Yan et al., 2015
(n = 22)
Gröer et al., 2014
(n = 25)
Achour et al., 2014
(n = 24)





1A1 33.2 (4)b 18.3 (2) 124.0 (2) 21.7 (2) 20.2 (3) 33.6 (8) 31.7 (4) 34.3 (2)
1A3 17.3 (6) 9.9 (3) 20.6 (9) — 0.4 (4) 123.1 (1) 8.2 (7) 6.3 (9)
1A4 ND 4.6 (5) 84.0 (5) 28.2 (1) — 58.0 (6) 41.8 (2) 33.0 (4)
1A5 — — — — — — ND ND
1A6 114.0 (1) 5.2 (4) 22.6 (9) 12.0 (5) — 107.1 (2) 7.8 (8) 11.3 (7)
1A7 — ND ND — — — ND ND
1A8 — ND ND — — — ND ND
1A9 25.9 (5) 26.7 (1) 61.1 (7) 12.6 (4) — 40.0 (7) 21.8 (6) 22.7 (6)
1A10 ND ND ND — — — ND ND
2B4 — — 102.0 (3) — — 70.8 (4) 35.1 (3) 33.9 (3)
2B7 84.3 (2) — 200.0 (1) 21.0 (3) 24.1 (2) 82.9 (3) 67.7 (1) 69.4 (1)
2B10 — — 69.3 (6) — — — 5.4 (10)c 6.9 (8)c
2B15 61.8 (3) — 99.7 (4) — 27.9 (1) 62.1 (5) 28.8 (5) 30.2 (5)
2B17 — — 54.3 (8) — — — 7.3 (9) 4.9 (10)
ND, UGT not detected or below detection limit; -, UGT not measured.
aMeasured concentrations for each UGT in each individual is given in Supplemental Table 2.
bUGT rank order based on abundance.
cUGT2B10 concentration is underestimated because a coding single-nucleotide polymorphism is located in the sequence targeted by the signature peptide.
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based on the use of a multiplexed peptide concatamer strategy
(QconCAT) produced significantly different quantitative data than the
use of spiked labeled peptides, which will merit further investigation
(Achour et al., 2014).
Comparisons of hepatic UGT concentrations revealed high and
significant correlations for several UGTs (Supplemental Table 1). The
strongest correlation was found between UGT2B7 and UGT2B15
(r = 0.88, P , 0.001). UGT2B7 expression was also highly correlated
with UGT2B4 (r = 0.73, P , 0.001). Notably, UGT1A4 expression
correlated well with all measured UGTs besides UGT2B17, with the
highest correlations found with UGT1A6 and UGT2B4 (r $ 0.70,
P , 0.001). UGT1A6 expression correlated well with UGT1A9,
UGT2B4, UGT2B7, and UGT2B15 (r = 0.65–0.70, P , 0.001). In
contrast, UGT1A1 expression moderately correlated only with UGT1A4
and UGT2B4 (r = 0.50 and r = 0.56 respectively, P, 0.001), and the
expression of UGT2B17 did not correlate with any of the measured
UGTs. These observations support the coregulated expression of several
UGTs by hepatic transcription factors, including the farnesoid X receptor
(UGT2B4 and UGT2B7) and hepatic nuclear factor 1a (most UGT1As
and UGT2Bs) (reviewed by Hu et al., 2014).
Quantification of Hepatic Glucuronidation Activity Using Probe
Substrates. The reliability of targeted proteomics quantification was
further established by correlating absolute concentrations with the
glucuronidation activity of selected probe substrates by the HLMs
(Fig. 2). The interindividual differences in hepatic glucuronidation
capacity ranged between 48% and 79%, in line with that of UGT
protein concentrations (Fig. 1).
UGT1A1 activity was established based on the formation of
bilirubin glucuronide, and it correlated well with the UGT1A1
protein concentrations measured by MRM (r = 0.88, P , 0.001; Fig.
2A). Furthermore, UGT1A1-dependent bilirubin-G and estradiol-3G
formation were significantly reduced by 45% and 37%, respectively,
in carriers of the variant UGT1A1*28 allele, as a consequence of the
reduced expression of UGT1A1 by 35% in carriers (Supplemental
Figure 1).
The concentrations of UGT1A4 and UGT1A6 were also highly
correlated with the glucuronidation of their respective probe substrates,
tacrolimus and deferiprone (Fig. 2, B and C). The correlation between
UGT2B7 activity and the glucuronidation of its probe substrate AZT
was similarly strong (r = 0.82, P , 0.001; Fig. 2E). Furthermore,
estradiol-3G formation strongly correlated with UGT1A1 concentra-
tions (r = 0.93, P, 0.001; Fig. 2A) whereas, as expected, estradiol-17G
correlated with UGT2B7 concentration (r = 0.84, P , 0.001; Fig. 2E)
(Lepine et al., 2004). UGT1A9-dependent conjugation of propofol was
the least but nonetheless well correlated with measured protein
concentrations (r = 0.72, P , 0.001; Fig. 2D).
Conclusion
This study establishes the concentration of human liver UGT
enzymes by targeted proteomics. We observed that the proteo-
mics quantification correlates well with the enzymatic activity
of main enzymes for a probe substrate, supporting the value of
multiplexed targeted quantitative proteomics to accurately assess
Fig. 1. Hepatic expression profiles of UGT proteins. (A) The absolute concentration of
UGTs was established by targeted quantitative proteomics analysis of 48 HLM fractions. The
mean concentration (pmol/mg proteins) and CV (%) are provided for each measured UGT.
(B) Relative abundance of hepatic UGTs based on average concentrations.
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